Bone-Seeking Targeted Radio-Nuclide Therapy BT-RNT) in Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC): Shifting fromPalliation to Improving Survival

  title={Bone-Seeking Targeted Radio-Nuclide Therapy BT-RNT) in Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC): Shifting fromPalliation to Improving Survival},
  author={Vimoj Nair and Colin C. Malone and Patr{\'i}cia Moretto and Eugene Leung and Shawn Malone},
  journal={Journal of Nuclear Medicine and Radiation Therapy},
Background: The purpose of this article is to review the role of bone-seeking targeted radionuclide therapy (BT-RNT) in metastatic prostate cancer. The mechanisms of actions, radiobiology and clinical benefits of BT-RNTs will be reviewed. Methods: Relevant studies of CRPC and targeted therapies were identified from literature and clinical trial databases, websites, and conference abstracts. Results: BT-RNT in mCRPC has a proven beneficial palliative role in treatment of patients with mCRPC… 
2 Citations

Figures and Tables from this paper

A Review on Most Common Male Malignancy - Prostate cancer

The study includes a detailed study of treatment for the prostate cancer, varying from stage to stage, and also a detail study about the diagnosis and the treatment.



Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease

Pending regulatory approval, 223Ra may represent a unique and distinct option for an important subgroup of patients with mCRPC; future trials should address its use in combination or in sequence with existing and novel agents.

Combining 153Sm-lexidronam and docetaxel for the treatment of patients with hormone-refractory prostate cancer: first experience.

The analysis demonstrates feasibility and therapeutic potential for the combination treatment and merits prospective investigation and further studies will be planned with respect to the potentially synergistic hematologic toxicity of bone-seeking radiopharmaceuticals and chemotherapy.

The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases.

  • M. Tomblyn
  • Medicine
    Cancer control : journal of the Moffitt Cancer Center
  • 2012
Targeted bone-seeking radionuclides are underutilized in the treatment of painful diffuse osteoblastic metastases and may offer a new class of agents that provide greater efficacy and less toxicity than those currently available for routine clinical use.

Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.

89Sr has proven to be efficacious in the palliation of hormone-refractory painful bone metastases from prostate cancer, but there is limited evidence on the relative efficacy of 89Sr compared with wide-field radiotherapy.

Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.

  • C. ParkerD. Heinrich A. Sartor
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
Ra-223 is an effective therapy that improved OS with a highly favorable safety profile, and may provide a new standard of care for the treatment of CRPC pts with bone mets.

Bone-seeking radionuclides for therapy.

  • V. Lewington
  • Medicine
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 2005
It is likely that targeted therapy will be most effective in the context of multimodality tumor management, and research is required to examine the potential of radionuclides in combination with external-beam irradiation, bisphosphonates, or chemotherapy.

Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer.

The role of bone-targeted radioisotope therapy in the setting of multimodality therapy for advanced prostate cancer is investigated to evaluate whether dose escalation, newer generations, or repeated dosing of radiopharmaceuticals enhance their antitumor effects and whether their combination with hormone ablative therapy, chemotherapy, or novel targeted therapy can improve clinical efficacy.

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.

  • K. FizaziP. Beuzeboc A. Laplanche
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
Combining docetaxel and samarium-153-EDTMP in patients with bone metastases from CRPC is well tolerated, and it yields major pain relief that persists long after treatment, and overall survival compares favorably with that expected in this population of patients.